Simvastatin and oseltamivir combination therapy does not improve the effectiveness of oseltamivir alone following highly pathogenic avian H5N1 influenza virus infection in mice
Simvastatin and oseltamivir combination therapy does not improve the effectiveness of oseltamivir alone following highly pathogenic avian H5N1 influenza virus infection in mice
复制标题
DOI：
10.1016/j.virol.2013.01.017
复制
发表时间：
2013-04-25
期刊：
影响因子：
3.7
通讯作者：
Tumpey, Terrence M.
中科院分区：
文献类型：
--
作者：
Belser, Jessica A.;Szretter, Kristy J.;Tumpey, Terrence M.
非特异性抗炎药据称可以减轻严重流感疾病的负担。我们证明，与奥司他韦给药不同，辛伐他汀给药不会降低感染 H1N1 或 H5N1 病毒的小鼠的发病率、死亡率或病毒载量。当小鼠与辛伐他汀联合治疗时，没有观察到奥司他韦治疗功效的额外益处。 H5N1 病毒感染的辛伐他汀治疗小鼠肺细胞因子的产生略有减少，但 H1N1 病毒感染的小鼠则不然，这表明使用他汀类药物在减轻严重病毒感染后的疾病方面具有潜在的益处。由爱思唯尔公司出版
Nonspecific anti-inflammatory drugs have been purported to reduce the burden of severe influenza disease. We demonstrate that, unlike oseltamivir administration, simvastatin administration did not reduce morbidity, mortality, or viral load of mice infected with H1N1 or H5N1 viruses. No added benefit to the efficacy of oseltamivir therapy was observed when mice were treated in combination with simvastatin. Modest reductions in lung cytokine production in H5N1 but not H1N1 virus-infected simvastatin-treated mice indicate a potential benefit for statin use in mitigating disease following severe virus infection. Published by Elsevier Inc.